Gossamer Bio Inc

Gossamer Bio has announced a private placement agreement valued at up to $250m, including $150m of committed capital to support development and potential FDA approval of seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The financing involves an initial closing of approximately $25m through pre-funded warrants priced at $0.14 per share, a subsequent closing of $125m contingent upon FDA acceptance of a new drug application, and warrants exercisable upon FDA approval that could add up to $100m more at $0.187 per share. Key institutional investors include EcoR1 Capital and RA Capital Management, with Leerink Partners and Cantor serving as joint placement agents. Gossamer plans to submit the NDA by September 2026, and net proceeds are expected to sustain operations until 2028.

Gossamer Bio plans to submit a New Drug Application for Seralutinib to treat pulmonary arterial hypertension in September 2026, while Forte Biosciences has agreed to be acquired by argenx for $77 per share in cash, representing a total equity value of roughly $2.2 billion. Gossamer also regained worldwide rights to Seralutinib from Chiesi and reported cash of approximately $57 million as of June 30, 2026. Entera Bio shares soared over 90% after announcing an oversubscribed private placement expected to generate about $275 million in gross proceeds. Omeros gained more than 15% after AstraZeneca's Ultomiris failed a Phase 3 trial for HSCT-TMA, removing a key competitive threat to Omeros's YARTEMLEA. First Tracks Biotherapeutics rose over 18%, continuing its strong performance since its April 2026 Nasdaq debut.

Gossamer Bio announced it will submit a New Drug Application for seralutinib in pulmonary arterial hypertension in September 2026, following a productive pre-NDA meeting with the FDA. If accepted, the inhaled therapy could receive an approval decision in the third quarter of 2027. The company also reacquired worldwide rights to seralutinib from Chiesi, securing full global control and the majority of long-term economics. Gossamer reported preliminary cash and equivalents of approximately $57 million as of June 30, 2026, and completed an exchange of about $181.1 million of its 2027 Notes for new 7.50% Convertible Senior Secured First Lien Notes due 2030. Shareholders approved a convertible note exchange and a reverse stock split, strengthening the capital structure ahead of the filing. The stock rose over 41% to $0.19.